Tolvaptan

Nature Reviews Drug Discovery

Volumn 8, Issue 8, 2009, Pages 611-612

  Ghali, Jalal K ^a   Hamad, Bashar ^b   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CONIVAPTAN; PLACEBO; SAMSCA; SODIUM; TOLVAPTAN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EUVOLEMIC HYPONATREMIA; HUMAN; HYPERVOLEMIC HYPONATREMIA; HYPONATREMIA; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VASOPRESSIN RELEASE;

BENZAZEPINES; DRUG APPROVAL; DRUG DISCOVERY; HUMANS; HYPONATREMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN;

EID: 68249091839     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2946     Document Type: Article

References (12)

1. Ghali, J. K. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology 111, 147-157 (2008).
2. Chen, S. et al. Evaluation and management of hyponatremia: An emerging role for vasopressin receptor antagonists. Nature Clin. Pract. Nephrol. 3, 82-95 (2007).
3. Ali, F. et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 67, 847-858 (2007).
4. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287, 860-867 (1998).
5. 2 receptor antagonist. Bioorg. Med. Chem. 7, 1743-1754 (1999).
6. 2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 146, 3037-3043 (2005).
7. Food and Drug Administration. FDA labelling information. FDA web site [online], http://www.accessdata.fda.gov/ drugsatfda_docs/label/2009/022275lbl.pdf (2009).
8. 2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355 2099-2112 (2006).
9. Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297, 1319-1331 (2007).
10. 2 antagonist. Cardiovascular Drug Rev. 25, 261-279 (2007).
11. Udelson, J. E. et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function inpatient with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49, 2151-2159 (2007).
12. IMS MIDAS MAT Q4 (IMS Health, 2008).